SolasCure announces final closing of GBP 10.9m (c. USD 13.3m) Series B fundraise to advance wound care innovation

SOLASCURE Ltd (SolasCure), a biotechnology company developing a hydrogel containing a recombinant enzyme derived from maggots which aims to accelerate wound debridement, has announced the completion of its GBP 10.9m (c. USD 13.3m) Series B investment round. The funding round was led by Seneca Partners and also included industry veterans, institutional venture and strategic investors, including BRAIN Biotech AG, EVA Pharma, Jonathan Milner, and Wealth Club.

SolasCure's first investigational product, Aurase Wound Gel, a hydrogel containing an enzyme cloned from medical maggots which aims to accelerate wound debridement, is due to enter further Phase II efficacy-supporting trials. The next phase of trials will include a larger and more diverse patient group compared to the Phase IIa safety study. The Company is hopeful that the results will continue to demonstrate how its innovative technology supports healthcare professionals treating patients with chronic wounds.

The pre-clinical trial results of SolasCure's Aurase Wound Gel, published in the International Wound Journal, showed preliminary evidence that supports its new enzymatic debridement product for use in chronic wounds. The enzyme is shown to have a good safety profile, both locally and systemically, which opens up a large therapeutic window. This has permitted SolasCure under regulatory review to test the enzyme on real patients with ulcers. SolasCure recently completed its CLEANVLU proof-of-concept first-in-man Phase IIa safety study examining the use of Aurase Wound Gel in chronic venous leg ulcer subjects. Results are now being collated and analysed, and more information will be available in the near future.

We would like to thank investors in our Series B round for continuing to support us as we progress our clinical development programme and focus on developing the efficacy of Aurase Wound Gel. We are excited to be working with such an experienced team, whose specialist knowledge is greatly valued in our mission to support healthcare professionals with wound care products that significantly improve outcomes for patients with chronic wounds.

Dr Sam Bakri, Founder & CEO, SolasCure

We are delighted to continue to support SolasCure through its latest funding round, following the impressive progress and positive results to date shown by the Aurase Wound Gel. We recognise great potential in the Company and support its mission to develop a potentially disruptive medical product that could displace its main competitor and achieve global commercial market success.

Matthew Currie, Investment Director, Seneca Partners

SolasCure was founded in 2017 as a spin-off from BRAIN Biotech AG, a leading German biotech company focused on harnessing biological diversity to develop innovative solutions.

We have been very pleased with the progress made by SolasCure during the clinical trial towards bringing this truly meaningful solution to patients. Our commitment to the Company is unchanged and we were happy to participate in the latest funding round.

Adriaan Moelker, CEO, BRAIN Biotech

For more information about SolasCure, please visit: https://solascure.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    SolasCure. (2023, March 27). SolasCure announces final closing of GBP 10.9m (c. USD 13.3m) Series B fundraise to advance wound care innovation. News-Medical. Retrieved on June 06, 2023 from https://www.news-medical.net/news/20230327/SolasCure-announces-final-closing-of-GBP-109m-(c-USD-133m)-Series-B-fundraise-to-advance-wound-care-innovation.aspx.

  • MLA

    SolasCure. "SolasCure announces final closing of GBP 10.9m (c. USD 13.3m) Series B fundraise to advance wound care innovation". News-Medical. 06 June 2023. <https://www.news-medical.net/news/20230327/SolasCure-announces-final-closing-of-GBP-109m-(c-USD-133m)-Series-B-fundraise-to-advance-wound-care-innovation.aspx>.

  • Chicago

    SolasCure. "SolasCure announces final closing of GBP 10.9m (c. USD 13.3m) Series B fundraise to advance wound care innovation". News-Medical. https://www.news-medical.net/news/20230327/SolasCure-announces-final-closing-of-GBP-109m-(c-USD-133m)-Series-B-fundraise-to-advance-wound-care-innovation.aspx. (accessed June 06, 2023).

  • Harvard

    SolasCure. 2023. SolasCure announces final closing of GBP 10.9m (c. USD 13.3m) Series B fundraise to advance wound care innovation. News-Medical, viewed 06 June 2023, https://www.news-medical.net/news/20230327/SolasCure-announces-final-closing-of-GBP-109m-(c-USD-133m)-Series-B-fundraise-to-advance-wound-care-innovation.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post